NO20054876L - Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser - Google Patents

Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser

Info

Publication number
NO20054876L
NO20054876L NO20054876A NO20054876A NO20054876L NO 20054876 L NO20054876 L NO 20054876L NO 20054876 A NO20054876 A NO 20054876A NO 20054876 A NO20054876 A NO 20054876A NO 20054876 L NO20054876 L NO 20054876L
Authority
NO
Norway
Prior art keywords
drug
compounds
phenyltetrahydroisoquinolines
substituted
preparation
Prior art date
Application number
NO20054876A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054876D0 (no
Inventor
Klaus Wirth
Hans-Jochen Lang
Wendelin Frick
Armin Hofmeister
Markus Bleich
Uwe Heinelt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054876D0 publication Critical patent/NO20054876D0/no
Publication of NO20054876L publication Critical patent/NO20054876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
NO20054876A 2003-03-24 2005-10-21 Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser NO20054876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312963A DE10312963A1 (de) 2003-03-24 2003-03-24 Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
PCT/EP2004/002497 WO2004085404A1 (fr) 2003-03-24 2004-03-11 4-phenyltetrahydroisoquinoleine substituee, son procede de fabrication, son utilisation comme medicament, et medicament contenant ce compose

Publications (2)

Publication Number Publication Date
NO20054876D0 NO20054876D0 (no) 2005-10-21
NO20054876L true NO20054876L (no) 2005-12-06

Family

ID=32946086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054876A NO20054876L (no) 2003-03-24 2005-10-21 Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser

Country Status (22)

Country Link
EP (1) EP1613600B1 (fr)
JP (1) JP2006521306A (fr)
KR (1) KR20050115304A (fr)
CN (1) CN100364978C (fr)
AR (1) AR043741A1 (fr)
AU (1) AU2004224242B2 (fr)
BR (1) BRPI0408744A (fr)
CA (1) CA2519658A1 (fr)
DE (1) DE10312963A1 (fr)
HR (1) HRP20050843A2 (fr)
MA (1) MA27751A1 (fr)
ME (1) MEP42908A (fr)
MX (1) MXPA05010003A (fr)
MY (1) MY139498A (fr)
NO (1) NO20054876L (fr)
NZ (1) NZ542608A (fr)
PE (1) PE20050311A1 (fr)
RS (1) RS20050713A (fr)
RU (1) RU2343147C2 (fr)
TW (1) TW200510321A (fr)
WO (1) WO2004085404A1 (fr)
ZA (1) ZA200506422B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012544A1 (de) 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2038264B1 (fr) * 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Arylamides substitués par tétrazole
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
MX2010012242A (es) * 2008-05-19 2010-12-06 Actelion Pharmaceuticals Ltd Tetrahidroisoquinolinas como agentes antimalariales.
WO2018129556A1 (fr) * 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
LT2748147T (lt) * 2011-08-25 2017-10-25 St. Jude Children`S Research Hospital 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizochinolin-4-karboksamidai, skirti antimaliarinei terapijai
HRP20191000T1 (hr) * 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
RU2538085C2 (ru) * 2013-05-08 2015-01-10 Любовь Демьяновна Шаманская Препарат для борьбы с экзопаразитами животных
RU2703456C2 (ru) * 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
EA202192414A1 (ru) * 2019-05-16 2022-03-02 Эли Лилли Энд Компани Соединения-ингибиторы натрий-водородного обменника 3
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JPH06256311A (ja) * 1993-02-26 1994-09-13 Nippon Shinyaku Co Ltd イソキノリノール誘導体及び医薬
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
NZ519146A (en) * 1999-11-03 2004-02-27 Albany Molecular Res Inc 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MXPA02004330A (es) * 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
EP1453810B1 (fr) * 2001-12-05 2009-03-18 Sanofi-Aventis Deutschland GmbH 4-phenyltetrahydroisoquinoleine, son procede de production, son utilisation comme medicament, et medicament la contenant
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline

Also Published As

Publication number Publication date
JP2006521306A (ja) 2006-09-21
TW200510321A (en) 2005-03-16
AU2004224242B2 (en) 2010-03-18
MY139498A (en) 2009-10-30
CN100364978C (zh) 2008-01-30
PE20050311A1 (es) 2005-06-06
HK1090042A1 (en) 2006-12-15
ZA200506422B (en) 2007-02-28
AU2004224242A1 (en) 2004-10-07
RU2343147C2 (ru) 2009-01-10
NO20054876D0 (no) 2005-10-21
KR20050115304A (ko) 2005-12-07
EP1613600A1 (fr) 2006-01-11
NZ542608A (en) 2009-07-31
MEP42908A (en) 2011-02-10
MXPA05010003A (es) 2005-11-17
CA2519658A1 (fr) 2004-10-07
RS20050713A (sr) 2007-11-15
HRP20050843A2 (en) 2006-09-30
WO2004085404A1 (fr) 2004-10-07
DE10312963A1 (de) 2004-10-07
AR043741A1 (es) 2005-08-10
CN1798737A (zh) 2006-07-05
RU2006127170A (ru) 2008-02-10
BRPI0408744A (pt) 2006-04-18
MA27751A1 (fr) 2006-02-01
EP1613600B1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
WO2005075425A3 (fr) Derives de bisaryluree
WO2007007919A3 (fr) Nouveaux composes
WO2008055870A8 (fr) Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication
WO2008034859A8 (fr) Dérivés du difluorobenzyl-benzène substitués par glucopyranosyle, médicament contenant ces composés, leur utilisation et procédé pour leur fabrication
WO2006067445A3 (fr) Composes chimiques
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
WO2006064033A3 (fr) Derives de benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
MX2009004908A (es) Compuestos quimicos.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2005037798A3 (fr) Nouveaux composés
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
MX2007003157A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento y un medicamento que las contiene.
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques